

DAFTAR PUSTAKA

- Abotaleb, M., Kubatka, P., Caprnda, M., Varghese, E., Zolakova, B., Zubor, P., ... & Büsselberg, D. (2018). Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. *Biomedicine & Pharmacotherapy*, 101, 458-477.
- Abbas S, Linseisen J, Slinger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D and Chang-Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. *Carcinogenesis* 2008; 29: 93-99.
- Abiltayeva A, Moore MA, Myssayev A, et al. Clinical, Histopathological and Molecular Characteristics of Metastatic Breast Cancer in North-Eastern Kazakhstan: a 10 Year Retrospective Study. *Asian Pacific J Cancer Prev* 2016; 17: 4797–4802.
- Agnieszka M, Magdalena K, Grazyna J, Iwanowicz P. Assessment of midwifery student preparation for performing the role of breast cancer educator. *Asian Pac J Cancer Prev*. 2014;15:5633–8
- Alco G, Igdem S, Dincer M. Vitamin D levels in patients with breast cancer: importance of dressing style. *Asian Pac J Cancer Prev*. 2014;15:1357–62
- Ali AM, Provenzano E, Bartlett JM, Abraham J, Driver K, Munro AF, Twelves C, Poole CJ, Hiller L, Dunn JA, Earl HM, Caldas C and Pharoah PD. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. *Int J Cancer* 2013; 133: 1470-1478.
- Anderson B, Yip C, Smith R, Shyyan R, Sener S, Eniu A, et al. Guideline implementation for breast healthcare in low-income and middleincome countries: overview of the breast health global initiative global summit 2007. *Cancer*. 2008;113:2221–43.
- , Gul A. Breast, cervix and colorectal cancer knowledge among nurses in key. *Asian Pac J Cancer Prev*. 2014;15:2267–9.



- Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18–2-fluoro-2-deoxyd-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. *J Clin Oncol.* 2004;22:4357–68
- Anuradha D, Lakshmi A. Mucinous carcinoma of breast with neuroendocrine differentiation: a rare case report with review of literature. *Int J Res Med Sci.* 2017;2:1751-4
- Badar F, Faruqui Z, Uddin N. Management of breast lesions by breast physicians in a heavily populated south Asian developing country. *Asian Pac J Cancer Prev.* 2011;12:827-32
- Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. *N Engl J Med.* 2021;384(16):1529–1541.
- Bednarek A, Sahin A, Brenner A, Johnston D, Aldaz C. Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage. *Clin Cancer Res.* 1997;3(1):11–6.
- Berry D, Cronin K, Plevritis S, Fryback D, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. *N Engl J Med.* 2005;353:1784–92.
- Bonotto, M., Erratana, LGE, Oletto, CEP, Rioli, PD, Iangreco, MAG, *et al.*. Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. *The Oncologist* 2014;19:608–615
- Buonomo OC, Caredda E, Portarena I, et al. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. *PLoS One* 2017; 12: 1–17.
- Cejalvo, JM, Pascual, T, Martínez, AF, Maristany, FB, Gomis, RR, Perou CM, Muñoz, M, Prat, A. Clinical implications of the non-luminal intrinsic types in hormone receptor-positive breast cancer. *Cancer Treatment reviews* 67 (2018) 63–70.



- Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørli T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO and van de Vijver MJ. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. *Proc Natl Acad Sci U S A* 2005; 102: 3738-3743
- Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J Natl Cancer Inst* 2009; 101: 736-50
- Chen, Z., Yang, J., Li, S., Lv, M., Shen, Y., Wang, B., ... & Yang, J. (2017). Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. *PloS one*, 12(9), e0182397.
- Ciruelos E, Villagrasa P, Paré L, Oliveira M, de la Peña L, Pernas S, et al. Abstract P5–20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13–03) trial. *AACR*; 2018.
- Clauser P, Marino MA, Baltzer PA, Bazzocchi M, Zuiani C. Management of atypical lobular hyperplasia, atypical ductal hyperplasia, and lobular carcinoma in situ. *Exp Rev Anticancer ther.* 2016;16:335–6
- Coleman M, Quaresma M, Berrino F, Lutz JM, Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol.* 2008;9:730–56.
- Courtinard, C., Gourgou, S., Jacot, W., Carton, M., Guérin, O., Vacher, L. et al. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database. *BMC Medicine*, 2023; 21(87).
- Cragun. D., Weidner, A., Lewis, C., Bonner, D., Kim, J., Vadaparampil, S. T., & , T. (2017). Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. *Cancer*, 123(13), 2497-2505.



- Dai X, Chen A and Bai Z. Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. *Sci Rep* 2014; 4: 6566
- Di Leo A, Buyse M, Bleiberg H. Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. *Ann Oncol.* 2004;15(4):545–549.
- Eberl M, Sunga A, Farrell C, Mahoney M. Patients with a family history of cancer: identification and management. *JABFM.* 2005;18:211–7
- Errichetti E, Avellini C, Pegolo E, De Francesco V. Dermoscopy as a supportive instrument in the early recognition of erosive adenomatosis of the nipple and mammary paget's disease. *Ann Dermatol.* 2017;29:365–7.
- Fan JH, Zhang S, Yang H, et al. Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study. *Front Oncol* 2023; 13: 1–12.
- Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., ... & Ren, G. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes & diseases*, 5(2), 77-106.
- Ferlay J, Soerjomataram I, Ervik M. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer.* 2015;136:359–86.
- Franca A, Ferreira M, Franca J, Franca E, Honorio-Franca A. Breastfeeding and its relationship with reduction of breast cancer: a review. *Asian Pac J Cancer Prev.* 2012;13:5327–32
- Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U and Bruzzi P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: pooled analysis of randomized trials. *J Natl Cancer Inst* 2008; 100: 14-20.
- h A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ; Panel members. Strategies for subtypes-dealing with the diversity of breast cancer:



- highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann Oncol* 2011; 22: 1736-1747
- Gong Y, Liu YR, Ji P, et al. Impact of molecular subtypes on metastatic breast cancer patients: A SEER population-based study. *Sci Rep* 2017; 7: 1–10.
- Grigoryeva ES, A.Tashireva L, Alifanov V V., et al. Molecular subtype conversion in CTCs as indicator of treatment adequacy associated with metastasis-free survival in breast cancer. *Sci Rep* 2022; 12: 1–12.
- Haghighat S, Akbari M, Ghaffari S, Yavari P. Standardized breast cancer mortality rate compared to the general female population of Iran. *Asian Pac J Cancer Prev.* 2012;13:5525–8
- Han S, Guo Q, Wang T. Prognostic significance of interactions between ER alpha and ER beta and lymph node status in breast cancer cases. *Asian Pac J Cancer Prev.* 2013;14:6081-4.
- Hang, J. A., Sim, L., & Zakaria, Z. (2017). Non-invasive breast cancer assessment using magnetic induction spectroscopy technique. *International Journal of Integrated Engineering*, 9(2).
- Hartmann L, Sellers T, Frost M, Lingle W, Degnim A, Suman V. Benign breast disease and the risk of breast cancer. *New Engl J Med.* 2005;353:229–37.
- Hassiotou F, Geddes D. Anatomy of the human mammary gland: current status of knowledge. *Clin Anat.* 2013;26:29–48
- Hasson-Ohayon I, Goldzweig G, Braun M, Galinsky D. Women with advanced breast cancer and their spouses: diversity of support and psychological distress. *PsychoOncology.* 2010;19:1195–204
- Haviland, J. S., Mannino, M., Griffin, C., Porta, N., Sydenham, M., Bliss, J. M., & Yarnold, J. R. (2018). Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. *Radiotherapy and Oncology*, 126(1), 155-162.



F, Daan Khambri, Rony Rustam. The Relationship of Breast Cancer types with the Event of Metastasis in Dr. M. Djamil Hospital Padang. *sci Med J Biomed Transl Res* 2021; 5: 1199–1205.

- Hermansyah D, Pricilia G, Azrah A, et al. Correlation between grading histopathology and sentinel lymph node metastasis in early breast cancer in university of sumatera utara hospital. *Open Access Maced J Med Sci* 2021; 9: 679–682.
- Hotte SJ, Bjarnason GA, Heng DY, et al. Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. *Curr Oncol.* 2011;18 Suppl 2:S11–S19.
- Ho-Yen C, Bowen RL and Jones J. Characterization of basal-like breast cancer: an update. *Diagnostic Histopathology* 2012; 18: 104-111
- Husarik D, Steinert H. Single-photon emission computed tomography/computed tomography for sentinel node mapping in breast cancer. *Semin Nuclear Med.* 2007;37:29-33
- Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, Maublanc M. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. *Cancer.* 1990;66:119–29.
- Joglekar-Javadekar M, Van Laere S, Bourne M, Moalwi M, Finetti P, Vermeulen PB, et al. Characterization and targeting of platelet-derived growth factor receptor alpha (PDGFRA) in inflammatory breast cancer (IBC). *Neoplasia.* 2017;19:564–73
- Jung, J., Lee, S. H., Park, M., Youn, J. H., Shin, S. H., Gwak, H. S., & Yoo, H. (2018). Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis. *Journal of neuro-oncology*, 137(2), 295-302.
- Kabel, A. M. (2017). Tumor markers of breast cancer: New prospectives. *Journal of Oncological Sciences*, 3(1), 5-11.
- Kadivar M, Mafi N, Joulaee A. Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002–2011. *Asian Pac J Cancer Prev.* 2012;13:1881–6



Sato T, Watanabe T, Takemasa S, Masuhiro Y, Ohtake F. Function of clear sex hormone receptors in gene regulation. *Cancer Chemother Pharmacol.* 2005;56:4–9.

Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. *J Clin Oncol*. 2009; 27:5529–37

Keisch M, Vicini F, Kuske R, Hebert M, White J, Quiet C, et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. *Int J Radiat Oncol Biol Phys*. 2003;55:289-93

Kelly K, Dean J, Comulada W, Lee S. Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. *Eur Radiol*. 2010;20:734–42

Khazai L, Rosa M. Use of immunohistochemical stains in epithelial lesions of the breast. *Cancer Control*. 2015;22:220–5

Khoker S, Muhammad U, Masooma R, Naseem A, Afaf S. Clinico-pathologic profile of breast cancer patients in Pakistan: 10 years data of a local cancer hospital. *Asian Pac J Cancer Prev*. 2012;13:693–8

Kim J, Lee Y, Yoo T, et al. Organ-Specific Recurrence or Metastatic Pattern of Breast Cancer according to Biological Subtypes and Clinical Characteristics. *J Breast Dis* 2019; 7: 30–37.

Kim, C., Lee, J., Lee, W., & Kim, A. Changes in intrinsic subtype of breast cancer during tumor progression in the same patient. *International journal of clinical and experimental pathology*, 2015; 8(11), 15184.

Klebe M, Fremd C, Kriegsmann M, et al. Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A-Type Breast Cancer. *JCO Precis Oncol* 2020; 848–859.

Koczkodaj P, Sulkowska U, Gotlib J, et al. Breast cancer mortality trends in Europe among women in perimenopausal and postmenopausal age (45+). *Arch Med* 2020; 16: 146–156.



- Legendijk, M., van Maaren, M. C., Saadatmand, S., Strobbe, L. J., Poortmans, P. M., Koppert, L. B., ... & Siesling, S. (2018). Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients. *International journal of cancer*, 142(1), 165-175.
- Li, Z., Hu, P., Tu, J., Yu, N. Luminal B breast cancer: patterns of recurrence and clinical Outcome. *Oncotarget*, 2016; 7(40).
- Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L and Bergh J. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. *J Clin Oncol* 2012; 30: 2601-2608.
- Liu, S., Huang, J., Zhang, Y., Liu, Y., Zuo, S., & Li, R. (2019). MAP2K4 interacts with Vimentin to activate the PI3K/AKT pathway and promotes breast cancer pathogenesis. *Aging (Albany NY)*, 11(22), 10697.
- Mateo A, Pezzi T, Sundermeyer M, Kelley C, Klimberg V, Pezzi C. Chemotherapy significantly improves survival for patients with T1c-T2N0M0 medullary Breast cancer. *Ann Surg Oncol*. 2017;24:1050–6
- Matheka M, Mutebi M, Sayed S, et al. Metastatic breast cancer in Kenya: survival, prognosis and management at a tertiary referral centre. *Ecancermedicalscience* 2023; 17: 1–11.
- Merrill A, White A, Howard-McNatt M. Paget's disease of the breast: an institutional review and surgical management. *Am Surg*. 2017;83:96–8.
- Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, et al. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. *Ann Oncol Off J Eur Soc Med Oncol*. 2016;27(6):1029–34.
- Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. *Ann Oncol*. 2021;32 (8):994–1004.



- Moran M, Schnitt S, Giuliano A, Harris J, Khan S, Horton J. Society of surgical oncology-American society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. *Int J Rad Oncol Biol Phys*. 2014;88:553–64.
- Morikawa A and Henry NL. Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. *Clin Cancer Res* 2015;
- Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC and Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell* 2004; 6: 117-127
- Najafi B, Anvari S, Roshan ZA. Disease free survival among molecular subtypes of early stage breast cancer between 2001 and 2010 in Iran. *Asian Pacific J Cancer Prev* 2013; 14: 5811–5816.
- Neuman H, Morrogh M, Gonen M. Stage IV breast cancer in the Era of targeted therapy, Does surgery of the primary tumor matter. *Cancer*. 2015;116:1226–33
- Nie G, Wang H, Song Y, et al. Breast cancer in “young” women: Age cutoff and clinicopathologic features. *J Clin Oncol*; 35.
- Nourmoussavi, M., Pansegrau, G., Popescu, J., Hammond, G. L., Kwon, J. S., & Carey, M. S. (2017). Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause. *Cancer treatment reviews*, 55, 26-35.
- O’Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J and Millikan RC. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. *Clin Cancer Res* 2010; 16: 6100-6110
- Page K, Guttery D, Fernandez-Garcia D, Hills A, Hastings R, Luo J, et al. Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer. *Clin Chem*. 2017;63:532–



- Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J and Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med* 2004; 351: 2817-2826
- Panchal, H., & Matros, E. (2017). Current trends in post-mastectomy breast reconstruction. *Plastic and reconstructive surgery*, 140(5), 7S.
- Park S, Koo JS, Kim MS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. *Breast* 2012; 21: 50–57.
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D. Molecular portraits of human breast tumours. *Nature* 2000; 406: 747-752
- Pietrantonio F, Lonardi S, Corti F, et al. Nomogram to predict the outcomes of patients with microsatellite instability- high metastatic colorectal cancer receiving immune checkpoint inhibitors. *Journal for ImmunoTherapy of Cancer* 2021;9:e003370. doi:10.1136/ jitc-2021-003370.
- Prabhakaran S, Rizk V, Ma Z, Cheng C, Berglund A, Coppola D, et al. Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes. *Breast Cancer Res.* 2017;19:71–4.
- Prat A, Cheang MC, Galvan P, Nuciforo P, Pare L, Adamo B, et al. Prognostic value of intrinsic subtypes in hormone receptor-positive metastatic breast cancer treated with letrozole with or without lapatinib. *JAMA Oncol* 2016;2:1287–94.
- Priya V, Prasaad P. Tubulo-lobular carcinoma: a rare mixed invasive carcinoma of breast. *Int J Res Med Sci.* 2017;5:2818–20
- Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF and Ellis IO. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. *J Pathol* 2006; 198: 495-506



- Redhwan A, Al-Naggar D, Bobryshev Y, Chen R, Assabri A. Practice and barriers toward breast self-examination among young Malaysian women. *Asian Pac J Cancer Prev*. 2011;12:1173–8
- Richardson H, Johnston D, Pater J, Goss P. The national cancer institute of Canada clinical trials group MAP.3 trial: an international breast cancer prevention trial. *Curr Oncol*. 2007;14:89–96
- Rizka A, Akbar MK, Putri NA. Carcinoma mammae sinistra t4bn2m1 metastasis pleura. *Averrous J Kedokt dan Kesehat Malikussaleh* 2022; 8: 23.
- Rizzo A, Cusmai A, Acquafredda S, Rinaldi L, Palmiotti G. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. *Expert Opin Investig Drugs*. 2022;31(6):495–498.
- Rugo HS, Bardia A, Marmé F. *et al*. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. *JCO*; 2022.
- Salhia B, Tapia C, Ishak EA, et al. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. *BMC Womens Health*; 11. Epub ahead of print 2011. DOI: 10.1186/1472-6874-11-44.
- Segal R, Evans W, Johnson D, Smith J, Colletta S, Gayton J. Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. *J Clin Oncol*. 2001;19:657–65.
- Serrano, CS, Mies, BP, Cortes, MG, Salgado, AC, Abad, MF, Martinez-Jañez, N., Soriano, M. Impact of HER2 low (H2L) expression on prognosis in luminal locally advanced or metastatic breast cancer (BC): A retrospective study. *Annals of Oncology*. 2021; 32(S2).
- Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World J Clin Oncol*. 2014;5:283–8.
- Shamsi U, Khan S, Usman S, Soomro S, Azam I. A multicenter matched case control study of breast cancer risk factors among women in Karachi, Pakistan. *Asian Pac J Cancer Prev*. 2013;14:183–8



Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin.* 2013;63:11-30.

Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. *Proc Natl Acad Sci U S A* 2003; 100: 10393-10398.

Stefanovic, S., Deutsch, TM, Wirtz R, Hartkopf, A., Sinn, P., Kohler, M., Hofmann, J. *et al.* Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle. *Diagnostics* 2020; 10, 369.

Strode M, Khoury T, Mangieri C, Takabe K. Update on the diagnosis and management of malignant phyllodes tumors of the breast. *J Breast.* 2017;33:91–6

Sultana, R., Kataki, A. C., Borthakur, B. B., Basumatary, T. K., & Bose, S. (2017). Imbalance in leptin-adiponectin levels and leptin receptor expression as chief contributors to triple negative breast cancer progression in Northeast India. *Gene*, 621, 51-58.

Sundén M, Norgren S, Lundqvist R, et al. Receptor conversion and survival in breast cancer liver metastases. *Breast Cancer Res* 2023; 25: 1–10.

Tagliabue G, Fabiano S, Contiero P, et al. Molecular subtypes, metastatic pattern and patient age in breast cancer: An analysis of italian network of cancer registries (airtum) data. *J Clin Med*; 10. Epub ahead of print 2021. DOI: 10.3390/jcm10245873.

Tang, Y., Bycott, P., Åkerborg, Ö., Jönsson, L, dan Negrier, S. interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study. *Cancer Management and Research* 2014;6 365–37.

Tanis P, Nieweg O, Olmos R, Kroon B. Anatomy and physiology of lymphatic inage of the breast from the perspective of sentinel node biopsy1. *J Amer l Surg.* 2001;192:399–409



- Tedjamartono TD, Sudarsa IW, Winata A, et al. Overekspresi HER-2 sebagai faktor risiko terjadinya metastasis otak pada pasien kanker payudara. *J Med Udayana* 2020; 9: 58–64.
- Torre LA, Sauer AM, Chen MS, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, native hawaiians, and pacific islanders, 2016: converging incidence in males and females. *Cancer J Clin*. 2016;66:182–202
- Trisna WA, Sahudi S, Kusumastuti EH. Correlation Between Hormonal Status of Estrogen Receptor and Malignancy Degree of Invasive Ductal Breast Cancer. *Maj Biomorfologi* 2021; 31: 1.
- Turner KM, Yeo SK, Holm TM, et al. Heterogeneity within molecular subtypes of breast cancer. *Am J Physiol - Cell Physiol* 2021; 321: C343–C354.
- Vallejos CS, Gómez HL, Gruz WR, Pinto JA, Dyer RR, Velarde R, Suazo JF, Neciosup SP, M L, de la Cruz MA and Vigil CE. Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database. *Clinical Breast Cancer* 2010; 10: 294-300
- van Dooijeweert C, van Diest PJ, Ellis IO. Grading of invasive breast carcinoma: the way forward. *Virchows Arch* 2022; 480: 33–43.
- Van Seijen, M., Lips, E. H., Thompson, A. M., Nik-Zainal, S., Futreal, A., Hwang, E. S., ... & Wesseling, J. (2019). Ductal carcinoma in situ: to treat or not to treat, that is the question. *British journal of cancer*, 121(4), 285-292.
- Visvanathan K, Chlebowski R, Hurley P, Col F, Ropka M, Collyar D. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. *J Clin Oncol*. 2009;27:3235–58
- Wang GS, Zhu H, Bi SJ. Pathological features and prognosis of different molecular subtypes of breast cancer. *Mol Med Rep* 2012; 6: 779–782.
- Wang O, Sun L, Yan J, et al. Expression of vascular endothelial growth factor and pax-3 in mucinous breast carcinoma and infiltrating ductal carcinoma-not otherwise specified, and the correlation with disease-free survival. *Oncol Lett* .7; 14: 4890–4896.



- Weigelt B, Mackay A, A'Hern R, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. *Lancet Oncol* 2010;11(4): 339–49
- West A, Wullkopf L, Christensen A, Leijnse N, Tarp JM, Mathiesen J, et al. Division induced dynamics in non-Invasive and invasive breast cancer. *Biophys J*. 2017;112:123–5
- Wijayanto A, Pieter JSLA, Prihantono P, et al. Survivability Rates Based on Molecular Subtype, Stage and Metastasis of 36 months cohort in Breast Cancer Patients. *Nusant Med Sci J* 2022; 7: 29–38.
- Winer E, Hudis C, Burstein H, Wolff A, Pritchard K, Ingle J, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer: status report 2004. *J Clin Oncol*. 2005;23:619–29
- Wu, Y. P., Chen, S. H., Wang, S. T., Li, X. D., Cai, H., Lin, Y. Z., ... & Xu, N. (2017). Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study. *Oncotarget*, 8(17), 29048.
- Yang L, Parkin D, Ferlay J. Estimates of cancer incidence in China for 2000 and projections for 2005. *Cancer Epidemiol Biomarkers Prev*. 2005;14:243–50
- Zavyalova M V., Denisov E V., Tashireva LA, et al. Phenotypic drift as a cause for intratumoral morphological heterogeneity of invasive ductal breast carcinoma not otherwise specified. *Biores Open Access* 2013; 2: 148–154.
- Zhao M, Howard E, Parris A, Guo Z, Zhao Q, Yang X. Alcohol promotes migration and invasion of triple-negative breast cancer cells through activation of p38 MAPK and JNK. *Mol Carcinogen*. 2017;56:849–62
- Ziperstein MJ, Guzman A, Kaufman LJ. Evaluating breast cancer cell morphology as a predictor of invasive capacity. *Biophys J*. 2016;110:621–5.



LAMPIRAN 1

REKOMENDASI ETIK



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpCK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 859/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 13 Nopember 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23100801	No Sponsor	
Peneliti Utama	dr. Fitran Amansyah	Sponsor	
Judul Peneliti	Hubungan Subtipe Molekuler dengan Metastasis dan progresif Disease Free Survival pada Penderita Kanker Payudara		
No Versi Protokol	1	Tanggal Versi	29 Oktober 2023
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin dan RSUP Dr Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 13 Nopember 2023 sampai 13 Nopember 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



Optimized using
trial version
www.balesio.com

LAMPIRAN 2

DAFTAR RIWAYAT HIDUP

I. DATA PRIBADI

Nama lengkap : dr. Fitran Amansyah
Tempat/ tanggal lahir : Ujung Pandang, 16 Juni 1985
Jenis Kelamin : Laki-laki
Status kewarganegaraan: Indonesia
Agama : Islam
Alamat Korespondensi : Jln. H. Milun No 67 Bekasi
Telepon : 085256025865
E-Mail : fi6ams@gmail.com



II. RIWAYAT PENDIDIKAN

- 1991 – 1997 : SDN 6 Bontokamase
- 1997 – 2000 : SMP Negeri 3 Makassar
- 2000 – 2003 : SMA Negeri 1 Makassar
- 2003 – 2005 : Prodi Akuntansi Fakultas Ekonomi Universitas Hasanuddin (tidak tamat)
- 2005 – 2009 : Program Studi Sarjana Kedokteran Fakultas Kedokteran Universitas Sam Ratulangi
- 2009 – 2012 : Program Studi Profesi Dokter Fakultas Kedokteran Universitas Sam Ratulangi
- 2019 – 2023 : Program Studi Ilmu Bedah Fakultas Kedokteran Universitas Hasanuddin

III. KURSUS/PELATIHAN



kursus Definitive Surgical Trauma Care (DSTC), on March 26-27th 2022,
which presented by Indonesian Surgeons Association “IKABI”

- Kursus Bedah Laparoskopik Dasar on Feb 18-19th 2022, which presented by Indonesian Surgeons Association “IKABI”
- Workshop on Upper & Lower GI Endoscopy on March 11th, 2022, which presented by Indonesian Surgeons Association “IKABI”
- Kursus Ultrasonografi pada Trauma Thoraks dan Abdomen on Feb 8-9th, 2023, which presented by Indonesian Surgeons Association “IKABI” and Perhimpunan Ultrasonik Kedokteran Indonesia
- Emergency Management of Severe Burns Course on September, 17th 2021, which presented by Australian & New Zealand Burn Association
- Wound and Stoma Care Course on April, 10th 2019, which presented by Indonesian Surgeons Association “IKABI”
- Approach to Parenteral Nutrition of the ESPEN Life-Long Learning Programme” on April 2019, which presented by ESPEN
- Basic Surgical Skills on April 7th-9th, 2019 which presented by Indonesian Surgeons Association “IKABI”
- Advanced Trauma Life Support (ATLS) on 2015, which presented by Indonesian Surgeons Association “IKABI”
- Basic Surgical Skills Course for General Practitioner on 2019 which presented by Faculty of Medicine University of Padjajaran and Kolegium Ilmu Bedah Indonesia
- Advanced Cardiac Life Support (ACLS) Training on 2013 and 2017 which presented by Indonesian Heart Association
- Workshop Interaktif Electrocardiography (ECG) untuk dokter umum – RS PELNI 2014
- Workshop Patient Safety and Risk Management on 2016 which presented by PERSI an KARS
- Pelatihan Tatalaksanaan Pengendalian Program Tuberkulosis on 2014 which presented by Dinas Kesehatan DKI Jakarta
- Pelatihan Pengendalian Kinerja Rumah Sakit melalui Optimalisasi SPI on 2017 which presented by ARSADA



IV. RIWAYAT PENELITIAN DAN PUBLIKASI

Characteristics of Marine Envenomation Cases in Kepulauan Seribu District



Optimized using
trial version
www.balesio.com